Abstract

BACKGROUND AND AIMS

It is unclear whether hematuria is a risk factor for chronic kidney disease (CKD) progression. In addition, quantitative evaluation considering urine concentration as in proteinuria has not been established in hematuria. The aim of this study is to verify the relationship between semi-quantitative analysis of hematuria normalized for urine concentration and the progression in CKD.

METHOD

We analyzed 1909 patients with pre-dialysis CKD from KNOW-CKD cohort who assessed baseline urine microscopy. Patients were scored according to the number of red blood cells (RBC) in high power field (1 point for < 1, 2 points for 1–4, 3 points for 5̵119 and 4 points for ≥ 20). To obtain the hematuria score, these points were divided by the random urine creatinine level and multiplied by 100. The study endpoint was CKD progression, defined as a composite of a ≥ 50% decrease in estimated glomerular filtration rate (eGFR) from baseline values or end-stage kidney disease.

RESULTS

The hematuria score ranged from 1.86 to 20.3 (2.2 ± 1.86). During a median follow-up of 4.6 years (9657 person-years), 729 patients reached study endpoint. There was a graded association between hematuria score and the risk of progression of CKD. The hazard ratios (95% confidence intervals) for second, third and fourth quartile of hematuria score were 1.32 (1.04–1.67), 1.43 (1.12–1.82) and 1.50 (1.17–1.91), respectively, compared to the first quartile. For each 1 point increase in hematuria score, the risk of progression increased by 5%.

CONCLUSION

This study showed that there was a graded relationship between a new hematuria score and the risk of the progression of CKD. Microscopic hematuria is a risk factor for CKD progression and might be used as a quantitative risk assessment tool.

Table 1.

The association between hematuria score and the progression of CKD

Model 1Model 2Model 3
Hematuria scoreHRs (95% CI)PHRs (95% CI)PHRs (95% CI)P
Continuous1.09 (1.05–1.12)< .0011.08 (1.05–1.12)< .0011.05 (1.01–1.09).017
Quartile
1ReferenceReferenceReference
21.72 (1.37–2.16)< .0011.68 (1.33–2.11)< .0011.32 (1.04–1.67).021
31.90 (1.51–2.40)< .0011.83 (1.44–2.31)< .0011.43 (1.12–1.82).004
42.38 (1.91–2.98)< .0012.40 (1.91–3.03)< .0011.50 (1.17–1.91).001
Model 1Model 2Model 3
Hematuria scoreHRs (95% CI)PHRs (95% CI)PHRs (95% CI)P
Continuous1.09 (1.05–1.12)< .0011.08 (1.05–1.12)< .0011.05 (1.01–1.09).017
Quartile
1ReferenceReferenceReference
21.72 (1.37–2.16)< .0011.68 (1.33–2.11)< .0011.32 (1.04–1.67).021
31.90 (1.51–2.40)< .0011.83 (1.44–2.31)< .0011.43 (1.12–1.82).004
42.38 (1.91–2.98)< .0012.40 (1.91–3.03)< .0011.50 (1.17–1.91).001

Model 1: Unadjusted

Model 2: Adjusted for age, sex, body mass index, systolic blood pressure, diabetes, cardiovascular disease, dyslipidemia and renin-angiotensin-system inhibitor.

Model 3: Adjusted for model 2 + estimated glomerular filtration rate, hemoglobin, C-reactive protein, random urine protein to creatinine ratio, phosphorus, parathyroid hormone and smoking status.

HRs, hazard ratios; CI, confidence interval.

Table 1.

The association between hematuria score and the progression of CKD

Model 1Model 2Model 3
Hematuria scoreHRs (95% CI)PHRs (95% CI)PHRs (95% CI)P
Continuous1.09 (1.05–1.12)< .0011.08 (1.05–1.12)< .0011.05 (1.01–1.09).017
Quartile
1ReferenceReferenceReference
21.72 (1.37–2.16)< .0011.68 (1.33–2.11)< .0011.32 (1.04–1.67).021
31.90 (1.51–2.40)< .0011.83 (1.44–2.31)< .0011.43 (1.12–1.82).004
42.38 (1.91–2.98)< .0012.40 (1.91–3.03)< .0011.50 (1.17–1.91).001
Model 1Model 2Model 3
Hematuria scoreHRs (95% CI)PHRs (95% CI)PHRs (95% CI)P
Continuous1.09 (1.05–1.12)< .0011.08 (1.05–1.12)< .0011.05 (1.01–1.09).017
Quartile
1ReferenceReferenceReference
21.72 (1.37–2.16)< .0011.68 (1.33–2.11)< .0011.32 (1.04–1.67).021
31.90 (1.51–2.40)< .0011.83 (1.44–2.31)< .0011.43 (1.12–1.82).004
42.38 (1.91–2.98)< .0012.40 (1.91–3.03)< .0011.50 (1.17–1.91).001

Model 1: Unadjusted

Model 2: Adjusted for age, sex, body mass index, systolic blood pressure, diabetes, cardiovascular disease, dyslipidemia and renin-angiotensin-system inhibitor.

Model 3: Adjusted for model 2 + estimated glomerular filtration rate, hemoglobin, C-reactive protein, random urine protein to creatinine ratio, phosphorus, parathyroid hormone and smoking status.

HRs, hazard ratios; CI, confidence interval.

This content is only available as a PDF.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.